Evaxion Biotech A/S (NASDAQ:EVAX) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX) in a research report report published on Monday,Benzinga reports. They currently have a $14.00 target price on the stock.

Evaxion Biotech A/S Price Performance

Shares of NASDAQ EVAX opened at $2.40 on Monday. The firm has a 50-day moving average of $4.88 and a two-hundred day moving average of $10.66. The company has a market capitalization of $2.81 million, a price-to-earnings ratio of -1.66 and a beta of -0.28. The company has a current ratio of 1.00, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99. Evaxion Biotech A/S has a twelve month low of $2.22 and a twelve month high of $23.70.

Hedge Funds Weigh In On Evaxion Biotech A/S

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC acquired a new stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned approximately 2.98% of Evaxion Biotech A/S at the end of the most recent quarter. 11.04% of the stock is currently owned by institutional investors and hedge funds.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.